Compare DIAX & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DIAX | FDMT |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 525.1M | 515.6M |
| IPO Year | N/A | 2019 |
| Metric | DIAX | FDMT |
|---|---|---|
| Price | $14.10 | $9.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $31.71 |
| AVG Volume (30 Days) | 76.3K | ★ 755.3K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 7.93% | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $13.01 | $2.89 |
| 52 Week High | $15.85 | $12.34 |
| Indicator | DIAX | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 30.87 | 52.29 |
| Support Level | $13.73 | $8.41 |
| Resistance Level | $14.45 | $10.19 |
| Average True Range (ATR) | 0.21 | 0.69 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 10.26 | 49.59 |
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).